The pen is mightier than the sword - A picture is worth a thousand words

itc racing

↑ Grab this Headline Animator

All visitors are now able to view this blog over an encrypted connection by visiting

Tuesday, June 7, 2016

Why We're Watching Valeant Pharmaceuticals: TheStreet

Published on 6 Jun 2016
Valeant Pharmaceuticals is set to release results before the bell Tuesday. Analysts are anticipating the Botox maker to report adjusted earnings of $1.36 a share, that's down $1 from a year ago. Revenue estimates for this quarter are expected to grow about 8.7% to about $2.4 billion. Tuesday is Valeant's second quarterly report since its pricing and compliance scandals were revealed. The Fill or Kill team will be keeping a close eye on whether or not Valeant will beat top and bottom line estimates.. and if there is any further information on how the drug maker plans to reduce its debt.

No comments: